Glucotrack Announces Reverse Stock Split to Regain Nasdaq Compliance
GCTK sits 32% above its 52-week low of $0.25 on light trading volume (0.1× avg).
Summary
Glucotrack has announced a reverse stock split, a move that follows months of proxy filings seeking shareholder approval for a 1-for-30 split to avoid Nasdaq delisting. The company's Q2 10-Q revealed a cash crisis, going concern doubt, and expanded delisting risk, making this split a critical step to maintain its listing. The announcement confirms the board is proceeding with the split, though the exact ratio and effective date are not specified in the headline. This is a material corporate action that directly impacts share count and price, and traders will need to adjust positions accordingly. The reverse split is likely to be followed by further dilutive financings, as the company has already secured a $50M equity line and converted bridge notes at deep discounts.
At the time of this announcement, GCTK was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.25 to $14.14. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.